0001104659-19-032915.txt : 20190530
0001104659-19-032915.hdr.sgml : 20190530
20190530212610
ACCESSION NUMBER: 0001104659-19-032915
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190528
FILED AS OF DATE: 20190530
DATE AS OF CHANGE: 20190530
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BINGHAM KATE
CENTRAL INDEX KEY: 0001185040
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38916
FILM NUMBER: 19868372
MAIL ADDRESS:
STREET 1: 1365 MAIN STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BICYCLE THERAPEUTICS plc
CENTRAL INDEX KEY: 0001761612
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
BUSINESS ADDRESS:
STREET 1: B900 BABRAHAM RESEARCH CAMPUS
CITY: CAMBRIDGE
STATE: X0
ZIP: CB22 3AT
BUSINESS PHONE: 011441223261503
MAIL ADDRESS:
STREET 1: B900 BABRAHAM RESEARCH CAMPUS
CITY: CAMBRIDGE
STATE: X0
ZIP: CB22 3AT
FORMER COMPANY:
FORMER CONFORMED NAME: BICYCLE THERAPEUTICS Ltd
DATE OF NAME CHANGE: 20181212
4
1
a4.xml
4
X0306
4
2019-05-28
0
0001761612
BICYCLE THERAPEUTICS plc
BCYC
0001185040
BINGHAM KATE
C/O BICYCLE THERAPEUTICS PLC
B900, BABRAHAM RESEARCH CAMPUS
CAMBRIDGE
X0
CB22 3AT
UNITED KINGDOM
1
0
0
0
Ordinary Shares
2019-05-28
4
C
0
874709
A
874709
I
By SV Life Sciences Fund V, L.P.
Ordinary Shares
2019-05-28
4
C
0
623196
A
1497905
I
By SV Life Sciences Fund V, L.P.
Ordinary Shares
2019-05-28
4
C
0
18485
A
18485
I
By SV Life Sciences Fund V Strategic Partners. L.P.
Ordinary Shares
2019-05-28
4
C
0
13169
A
31654
I
By SV Life Sciences Fund V Strategic Partners. L.P.
Ordinary Shares
2019-05-28
4
P
0
377732
14
A
1875637
I
By SV Life Sciences Fund V, L.P.
Ordinary Shares
2019-05-28
4
P
0
7983
14
A
39637
I
By SV Life Sciences Fund V Strategic Partners. L.P.
Series A Preferred Shares
2019-05-28
4
C
0
874709
D
Ordinary Shares
874709
0
I
By SV Life Sciences Fund V, L.P.
Series B1 Preferred Shares
2019-05-28
4
C
0
623196
D
Ordinary Shares
623196
0
I
By SV Life Sciences Fund V, L.P.
Series A Preferred Shares
2019-05-28
4
C
0
18485
D
Ordinary Shares
18485
0
I
By SV Life Sciences Fund V Strategic Partners. L.P.
Series B1 Preferred Shares
2019-05-28
4
C
0
13169
D
Ordinary Shares
13169
0
I
By SV Life Sciences Fund V Strategic Partners. L.P.
Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.
These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.
These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein
/s/ Lee Kalowski, as Attorney-in-Fact
2019-05-30